Francisco Chacón-Lozsán: Insights on Intermediate High Risk Pulmonary Embolism from ACVC 2026
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn:
”ACVC 2026 | Intermediate High Risk Pulmonary Embolism: Are we underestimating the danger.
At ACVC26, an important question was raised:
- Are intermediate high risk PE patients more unstable than we think
- The hidden risk in intermediate high risk PE
- Intermediate high risk PE is not benign.
Key determinants of worse outcome include:
- Right ventricular dysfunction RV greater than LV
- Elevated biomarkers
- Increased lactate levels
- Acute kidney injury
- Mean arterial pressure trends
These parameters identify patients closer to hemodynamic collapse than previously assumed
Lessons from PEITHO trial
In intermediate risk PE:
- Reduction in hemodynamic decompensation with thrombolysis
- No significant mortality reduction
- Increased major bleeding and intracranial hemorrhage
Clinical benefit is offset by safety concerns
Normotensive shock concept
A critical concept highlighted:
Shock without hypotension
Defined by:
- Elevated lactate
- Reduced urine output
- Worsening renal function
- Impaired tissue perfusion
These patients may appear stable but carry high mortality risk
Risk stratification beyond classical models
Additional tools improve identification of high risk patients:
- Critical Care Cardiology Trials Network classification
- Composite Pulmonary Embolism Shock Score CPES
Higher CPES scores:
- Associated with increased adverse outcomes
- Predict progression toward shock.
Clinical implication
Intermediate high risk PE requires:
- Early identification of deterioration signals
- Integration of imaging, biomarkers, and perfusion markers
- Recognition of normotensive shock.
A shift from static to dynamic risk assessment.
Take home message
Intermediate high risk PE is a dynamic and potentially unstable condition.
- Not all normotensive patients are low risk
- Early signs of hypoperfusion matter
- Risk scores and physiology must guide decisions.
We may indeed be underestimating the danger.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 16:53Sickle Cell Disease Care Varies by Region – ASH
-
Apr 15, 2026, 16:40Jorge Lima։ Understanding Recurrent Pregnancy Loss
-
Apr 15, 2026, 16:26Pregnancy-Induced Rise in FIX Activity – A Challenge to International Hemophilia Guidelines – JTH
-
Apr 15, 2026, 16:18Ken Checicki: How Restoring Blood Flow Can Solve Post – DVT Complications
-
Apr 15, 2026, 16:05Alisha Tuck: Ultrasound and Anticoagulation Management in Pregnancy – Why Anticoagulation Matters?